August 7, 2017 10:32 AM EDTUpdated 07:45 PM

FDA slams Vernalis with 2nd CRL in 3 months; Former Shkreli company KaloBios changes name

Shehla Shakoor

Managing Director

→ Three months after the FDA rejected its tweaked cold remedy CCP-07, Vernalis says regulators have followed up by putting CCP-08 into the

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA slams Vernalis with 2nd CRL in 3 months; Former Shkreli company KaloBios changes name

Shehla Shakoor

Managing Director

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

New fund will pressure flailing biotechs, as investor frustration boils over

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

FDA slams Ver­nalis with 2nd CRL in 3 months; For­mer Shkre­li com­pa­ny Kalo­Bios changes name

Managing Director

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA slams Vernalis with 2nd CRL in 3 months; Former Shkreli company KaloBios changes name